Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Birchmeier-Kohler, Carmen Prof. Dr. (1) Chen, Wei Prof. Dr. (2) Chu, Van Trung Dr. (1) Daumke, Oliver Prof. Dr. (2) Di Virgilio, Michela Prof. Dr. (1) Fälber, Katja Dr. (1) Graf, Robin Dr. (1) Hammes-Lewin, Annette Dr. (1) Heinemann, Udo Prof. Dr. (1) Hirsekorn, Antje (1) Hübner, Norbert Prof. Dr. (2) Kempa, Stefan Dr. (1) Kirchner, Marieluise Dr. (1) Klußmann, Enno PD Dr. (1) Landthaler, Markus Prof. Dr. (3) Lewin, Gary Prof. Dr. (2) Lusatis, Simone (1) Mastrobuoni, Guido Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (2) Ohler, Uwe Prof. Dr. (2) Panakova, Daniela Dr. (1) Patone, Giannino Dr. (1) Rajewsky, Klaus Prof. Dr. (2) Rajewsky, Nikolaus Prof. Dr. (1) Rocks, Oliver Dr. (2) Roske, Yvette Dr. (1) Scheidereit, Claus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (20) Sommer, Christian (1) Wanker, Erich Prof. Dr. (2) Wollert-Wulf, Brigitte (3) Wyler, Emanuel Dr. (2) Zauber, Henrik Dr. (6) Zinzen, Robert Patrick Dr. (1) Zühlke, Kerstin Dr. (1) (-) Daniel, Peter Prof. Dr. (1) (-) Janz, Martin Dr. (7) (-) Mathas, Stephan Dr. (11) (-) Biologie maligner Lymphome (13) Genetik und Genomik von Herz- Kreislauferkrankungen (2) Immunregulation und Krebs (1) Molekulare Immunologie und Gentherapie (5) Systembiologie von Gen-regulatorischen Elementen (1) Translationale Onkologie solider Tumore (1) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (3) 2004 (3) 2005 (3) (-) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (3) (-) 2015 (5) (-) 2016 (3) 2017 (5) 2018 (1) 2019 (2) 2020 (6) 2021 (3) 2022 (7) 2023 (10) 2024 (2) 13 Ergebnisse: Active Filter: Daniel, Peter Prof. Dr.Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner Lymphome200620152016 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 03. Mai 2016 / Proc Natl Acad Sci U S A Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells E. Derudder S. Herzog V. Labi T. Yasuda K. Köchert M. Janz A. Villunger M. Schmidt-Supprian K. Rajewsky 01. Juni 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas 01. Juli 2016 / Semin Hematol Hodgkin lymphoma: pathology and biology S. Mathas S. Hartmann R. Küppers 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert 17. März 2016 / Genome Med A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses K.A.P. de Oliveira E. Kaergel M. Heinig J.F. Fontaine G. Patone E.M. Muro S. Mathas M. Hummel M.A. Andrade-Navarro N. Hübner C. Scheidereit Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
03. Mai 2016 / Proc Natl Acad Sci U S A Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells E. Derudder S. Herzog V. Labi T. Yasuda K. Köchert M. Janz A. Villunger M. Schmidt-Supprian K. Rajewsky
01. Juli 2016 / Semin Hematol Hodgkin lymphoma: pathology and biology S. Mathas S. Hartmann R. Küppers
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert
17. März 2016 / Genome Med A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses K.A.P. de Oliveira E. Kaergel M. Heinig J.F. Fontaine G. Patone E.M. Muro S. Mathas M. Hummel M.A. Andrade-Navarro N. Hübner C. Scheidereit